GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CSL Ltd (ASX:CSL) » Definitions » Price-to-Owner-Earnings
中文

CSL (ASX:CSL) Price-to-Owner-Earnings : 43.85 (As of Apr. 24, 2024)


View and export this data going back to 1994. Start your Free Trial

CSL Price-to-Owner-Earnings Definition

As of today (2024-04-24), CSL's share price is A$278.45. CSL's Owner Earnings per Share (TTM) ended in Jun. 2023 was A$6.35. It's Price-to-Owner-Earnings for today is 43.85.


The historical rank and industry rank for CSL's Price-to-Owner-Earnings or its related term are showing as below:

ASX:CSL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 22.87   Med: 39.69   Max: 55.8
Current: 42.47

During the past 13 years, the highest Price-to-Owner-Earnings of CSL was 55.80. The lowest was 22.87. And the median was 39.69.


ASX:CSL's Price-to-Owner-Earnings is ranked worse than
58.62% of 174 companies
in the Biotechnology industry
Industry Median: 32.265 vs ASX:CSL: 42.47

As of today (2024-04-24), CSL's share price is A$278.45. CSL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$7.60. Therefore, CSL's PE Ratio for today is 36.64.

As of today (2024-04-24), CSL's share price is A$278.45. CSL's EPS without NRI for the trailing twelve months (TTM) ended in was A$7.60. Therefore, CSL's PE Ratio without NRI for today is 36.64.

During the past 13 years, CSL's highest PE Ratio without NRI was 55.28. The lowest was 22.25. And the median was 38.00.


CSL Price-to-Owner-Earnings Historical Data

The historical data trend for CSL's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CSL Price-to-Owner-Earnings Chart

CSL Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.26 45.60 49.15 43.37 43.72

CSL Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 43.37 - 43.72 -

Competitive Comparison of CSL's Price-to-Owner-Earnings

For the Biotechnology subindustry, CSL's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CSL's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CSL's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where CSL's Price-to-Owner-Earnings falls into.



CSL Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

CSL's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=278.45/6.35
=43.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CSL  (ASX:CSL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


CSL Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of CSL's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


CSL (ASX:CSL) Business Description

Industry
Traded in Other Exchanges
Address
655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.